{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:17:36Z","timestamp":1792682256199,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.clinthera.2008.02.002","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T15:11:31Z","timestamp":1208445091000},"page":"260-270","source":"Crossref","is-referenced-by-count":47,"title":["Effect of levetiracetam on cardiac repolarization in healthy subjects: A single-dose, randomized, placebo- and active-controlled, four-way crossover study"],"prefix":"10.1016","volume":"30","author":[{"given":"R\u00e9ginald","family":"Hulhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Rosillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Bridson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edubijes","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armel","family":"Stockis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.02.002_bib1","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clinthera.2008.02.002_bib2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000 mg\/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2008.02.002_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2008.02.002_bib4","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2008.02.002_bib5","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2008.02.002_bib6","first-page":"56","article-title":"Efficacy and safety of levetiracetam 3000 mg\/d as adjunctive treatment in adolescents and adults suffering from idio-pathic generalised epilepsy with myoclonic seizures","volume":"46","author":"Verdru","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2008.02.002_bib7","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2008.02.002_bib8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of leveti-racetam and controlled-release carba-mazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2008.02.002_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2008.02.002_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00228-003-0655-6","article-title":"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers","volume":"59","author":"Strolin Benedetti","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2008.02.002_bib13","doi-asserted-by":"crossref","first-page":"K105","DOI":"10.1016\/S1520-765X(01)90014-8","article-title":"Focus on issues in measuring and interpreting changes in the QTc interval duration","volume":"3","author":"Morganroth","year":"2001","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.clinthera.2008.02.002_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jelectrocard.2003.11.004","article-title":"A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment","volume":"37","author":"Morganroth","year":"2004","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.clinthera.2008.02.002_bib15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/0091270006286436","article-title":"Clinical evaluation of QT\/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline","volume":"46","author":"Darpo","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.02.002_bib16","first-page":"10","article-title":"A practical approach to cardiac safety: Implementing ICH E14 to define cardiac safety in new drug development","author":"Grisanti","year":"2005","journal-title":"Appl Clin Trials Suppl"},{"key":"10.1016\/j.clinthera.2008.02.002_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/009286150503900304","article-title":"Investigating drug-induced QT and QTc prolongation in the clinic: A review of statistical design and analysis considerations. Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team","volume":"39","author":"Patterson","year":"2005","journal-title":"Drug InfoJ"},{"key":"10.1016\/j.clinthera.2008.02.002_bib18","first-page":"1009","article-title":"Drugs, QTc interval prolongation and final ICH E14 guideline: An important milestone with challenges ahead","volume":"28","author":"Shah","year":"2005","journal-title":"DrugSaf"},{"key":"10.1016\/j.clinthera.2008.02.002_bib21","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1540-8159.2004.00701.x","article-title":"Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation","volume":"27","author":"Malik","year":"2004","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.clinthera.2008.02.002_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1528-1157.2003.25302.x","article-title":"Levetiracetam, a new antiepileptic agent: Lack of in vitro pharmacokinetic interaction with valproic acid","volume":"44","author":"Coupez","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2008.02.002_bib23","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1128\/AAC.42.8.2060","article-title":"Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects","volume":"42","author":"Stass","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.02.002_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003088-200140001-00004","article-title":"Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers","volume":"40","author":"Stass","year":"2001","journal-title":"Clin Pharma-cokinet"},{"key":"10.1016\/j.clinthera.2008.02.002_bib25","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/AAC.43.11.2793","article-title":"Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 128039), a new enantiomerically pure 8-methoxy quinolone","volume":"43","author":"Sullivan","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2008.02.002_bib26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0009-9236(03)00009-2","article-title":"Effects of three fluoroquinolones on QT interval in healthy adults after single doses","volume":"73","author":"Noel","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.02.002_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.clpt.6100010","article-title":"Cardiac repolarization and the safety of new drugs defined by electrocardiography","volume":"81","author":"Morganroth","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.02.002_bib28","series-title":"Pharmacometrics: The Science of Quantitative Pharmacology","first-page":"977","article-title":"Pharmacometric methods for assessing drug-induced QT and QTc prolongations for non-antiarrhythmic drugs","author":"Sun","year":"2006"},{"key":"10.1016\/j.clinthera.2008.02.002_bib29","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1177\/0091270005279010","article-title":"QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective antagonist for the treatment of overactive bladder","volume":"45","author":"Serra","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2008.02.002_bib30","doi-asserted-by":"crossref","first-page":"P10","DOI":"10.1016\/j.clpt.2004.11.040","article-title":"Darifenacin, an M3 selective receptor antagonist (M3 SAR), does not prolong QT\/QTc","volume":"77","author":"Skerjanec","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T12:12:01Z","timestamp":1557490321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0149291808000738"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.02.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}